Diabetes, Obesity and Metabolism

Cover image for Vol. 19 Issue 2

Accepted Articles (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

Edited By: R. Donnelly

Impact Factor: 6.198

ISI Journal Citation Reports © Ranking: 2015: 13/133 (Endocrinology & Metabolism)

Online ISSN: 1463-1326

VIEW

  1. 1 - 43
  1. ORIGINAL ARTICLES

    1. Comparative Effectiveness and Safety of Different Basal Insulins in a Real World Setting

      Linong Ji, Puhong Zhang, Dongshan Zhu, Juming Lu, Xiaohui Guo, Yangfeng Wu, Xian Li, Jiachao Ji, Weiping Jia, Wenying Yang, Dajin Zou, Zhiguang Zhou, Yan Gao, Satish K. Garg, Changyu Pan, Jianping Weng, Sanjoy K. Paul and on behalf of the ORBIT study group

      Accepted manuscript online: 23 FEB 2017 07:45AM EST | DOI: 10.1111/dom.12920

  2. BRIEF REPORTS

    1. Five-year cost-effectiveness of Patient Empowerment Programme (PEP) for type 2 diabetes mellitus in primary care

      JX Lian, Sarah M McGhee, C So, J Chau, Carlos KH Wong, William CW Wong and Cindy LK Lam

      Accepted manuscript online: 23 FEB 2017 07:35AM EST | DOI: 10.1111/dom.12919

    2. Effects of short-term energy restriction on liver lipid content and inflammatory status in severely obese adults: results of a randomised controlled trial (RCT) using two dietary approaches

      Emma L Baldry, Guruprasad P. Aithal, Philip Kaye, Iskandar R Idris, Andrew Bennett, Paul C Leeder and Ian A Macdonald

      Accepted manuscript online: 23 FEB 2017 07:10AM EST | DOI: 10.1111/dom.12918

  3. ORIGINAL ARTICLES

    1. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: a retrospective cohort study

      Sarah E. Holden, Christopher Ll. Morgan, Qing Qiao, Sara Jenkins-Jones, Ellen R. Berni and Craig J. Currie

      Accepted manuscript online: 20 FEB 2017 10:20AM EST | DOI: 10.1111/dom.12916

    2. Delays in treatment intensification with oral antidiabetic drugs and risk of microvascular and macrovascular events in patients with poor glycemic control: An individual patient simulation study

      Henry J. Folse, Jayanti Mukherjee, John J. Sheehan, Alexandra J. Ward, Ryan L. Pelkey, Tuan A. Dinh, Lei Qin and Jennifer Kim

      Accepted manuscript online: 17 FEB 2017 07:55AM EST | DOI: 10.1111/dom.12913

    3. Comparison of body mass index at diagnosis of diabetes in a multiethnic population: a case–control study with matched non-diabetic controls

      Sanjoy K. Paul, Ebenezer S. Owusu Adjah, Mayukh Samanta, Kiran Patel, Srikanth Bellary, Wasim Hanif and Kamlesh Khunti

      Accepted manuscript online: 17 FEB 2017 07:30AM EST | DOI: 10.1111/dom.12915

    4. Preclinical characterisation of 55P0251, a novel compound that amplifies glucose stimulated insulin secretion and counteracts hyperglycaemia in rodents

      Karin Stadlbauer, Barbara Brunmair, Zsuzsanna Lehner, Immanuel Adorjan, Thomas Scherer, Anton Luger, Leonhardt Bauer and Clemens Fürnsinn

      Accepted manuscript online: 17 FEB 2017 07:25AM EST | DOI: 10.1111/dom.12914

    5. AMP-activated protein kinase activator A-769662 increases intracellular calcium and ATP release from astrocytes in an AMPK-independent manner

      Julia M. Vlachaki Walker, Josephine L. Robb, Ana M. Cruz, Amrinder Malhi, Paul G. Weightman Potter, Michael L.J. Ashford, Rory J. McCrimmon, Kate L.J. Ellacott and Craig Beall

      Accepted manuscript online: 17 FEB 2017 07:00AM EST | DOI: 10.1111/dom.12912

  4. REVIEW ARTICLES

    1. Short-acting GLP-1 receptor agonists as add-on to insulin therapy in type 1 diabetes - a review

      Anders Albèr, Andreas Brønden and Filip K. Knop

      Accepted manuscript online: 17 FEB 2017 06:25AM EST | DOI: 10.1111/dom.12911

  5. ORIGINAL ARTICLES

    1. You have full text access to this OnlineOpen article
      Lipid-Lowering Efficacy and Safety of Alirocumab in Patients with or without Diabetes: A Sub-Analysis of ODYSSEY COMBO II

      Lawrence A. Leiter, Jose Luis Zamorano, Maja Bujas-Bobanovic, Michael J. Louie, Guillaume Lecorps, Christopher P. Cannon and Yehuda Handelsman

      Accepted manuscript online: 16 FEB 2017 05:30AM EST | DOI: 10.1111/dom.12909

    2. Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes

      Ziad H. Al-Oanzi, Sophia Fountana, Tabassum Moonira, Susan J Tudhope, John L. Petrie, Ahmed Alshawi, Gillian Patman, Catherine Arden, Helen L. Reeves and Loranne Agius

      Accepted manuscript online: 16 FEB 2017 05:30AM EST | DOI: 10.1111/dom.12910

    3. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study

      Kishore M. Gadde, Marion L. Vetter, Nayyar Iqbal, Elise Hardy, Peter Öhman and on behalf of the DURATION-NEO-2 study investigators

      Accepted manuscript online: 16 FEB 2017 04:20AM EST | DOI: 10.1111/dom.12908

  6. BRIEF REPORTS

    1. Evaluation of Subcutaneous Glucose Monitoring Systems under Routine Environmental Conditions in Patients with Type 1 Diabetes

      Felix Aberer, Martin Hajnsek, Markus Rumpler, Sabine Zenz, Petra Baumann, Hesham Elsayed, Adelheid Puffing, Gerlies Treiber, Thomas R. Pieber, Harald Sourij and Julia K. Mader

      Accepted manuscript online: 16 FEB 2017 03:50AM EST | DOI: 10.1111/dom.12907

  7. ORIGINAL ARTICLES

    1. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase 4 inhibitors versus therapeutic alternatives

      Mugdha Gokhale, John B. Buse, Michele Jonsson Funk, Jennifer Lund, Virginia Pate, Ross J Simpson and Til Stürmer

      Accepted manuscript online: 14 FEB 2017 07:35AM EST | DOI: 10.1111/dom.12906

    2. Baseline Adiponectin Concentration and Clinical Outcomes among Patients with Diabetes and Recent Acute Coronary Syndrome in the EXAMINE Trial

      Brian A. Bergmark, Christopher P. Cannon, William B. White, Petr Jarolim, Yuyin Liu, Marc P. Bonaca, Faiez Zannad and David A. Morrow

      Accepted manuscript online: 14 FEB 2017 06:20AM EST | DOI: 10.1111/dom.12905

    3. Treatment with the Glucagon Receptor Antagonist LY2409021 Increases Ambulatory Blood Pressure in Patients with Type 2 Diabetes

      Christof M. Kazda, Juan Frias, Irene Foga, Xuewei Cui, Cristina B. Guzman, Parag Garhyan, Cory Heilmann, Jihui Anne Yang and Thomas A. Hardy

      Accepted manuscript online: 13 FEB 2017 11:05AM EST | DOI: 10.1111/dom.12904

  8. BRIEF REPORTS

    1. Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomised double-blinded placebo-controlled clinical trial

      Peter G. Jørgensen, Magnus T. Jensen, Pernille Mensberg, Heidi Storgaard, Signe Nyby, Jan S. Jensen, Filip K. Knop and Tina Vilsbøll

      Accepted manuscript online: 11 FEB 2017 08:00AM EST | DOI: 10.1111/dom.12900

    2. Hypoglycemia manifestations and recurrent events: lessons from the SAVOR-TIMI 53 outcome study

      Avivit Cahn, Ofri Mosenzon, Deepak L. Bhatt, Gil Leibowitz, Ilan Yanuv, Aliza Rozenberg, Nayyar Iqbal, Boaz Hirshberg, Christina Stahre, KyungAh Im, Estella Kanevsky and Itamar Raz

      Accepted manuscript online: 9 FEB 2017 08:15AM EST | DOI: 10.1111/dom.12903

  9. ORIGINAL ARTICLES

    1. A comparison of the effects of diets high in animal or plant protein on metabolic and cardiovascular markers in type 2 diabetes – a randomized clinical trial

      Stephanie Sucher, Mariya Markova, Silke Hornemann, Olga Pivovarova, Natalia Rudovich, Ralph Thomann, Rosemarie Schneeweiss, Sascha Rohn and Andreas F. H. Pfeiffer

      Accepted manuscript online: 9 FEB 2017 08:15AM EST | DOI: 10.1111/dom.12901

    2. You have full text access to this OnlineOpen article
      Treatment Patterns in Patients with Type 2 Diabetes Mellitus Treated with GLP-1 Receptor Agonists: Higher Adherence and Persistence with Dulaglutide Compared to Exenatide QW and Liraglutide

      C Alatorre, L Fernández Landó, M Yu, K Brown, L Montejano, P Juneau, R Mody and R Swindle

      Accepted manuscript online: 9 FEB 2017 08:15AM EST | DOI: 10.1111/dom.12902

    3. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24-week, randomised, double-blind, placebo-controlled trial

      Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Hiroaki Iijima, Yumi Watanabe and Maki Gouda

      Accepted manuscript online: 8 FEB 2017 05:35AM EST | DOI: 10.1111/dom.12898

    4. Acute physiological effects of glucocorticoids on fuel metabolism in humans are permissive but not direct

      Roland H Stimson, Anna J Anderson, Lynne E Ramage, David P Macfarlane, Andrew C de Beaux, Damian J Mole, Ruth Andrew and Brian R Walker

      Accepted manuscript online: 8 FEB 2017 05:30AM EST | DOI: 10.1111/dom.12899

  10. LETTER TO THE EDITOR

    1. Glp-1 receptor agonists and sglt-2 inhibitors: Sequential or simultaneous start?

      Edison Goncalves and David SH Bell

      Accepted manuscript online: 8 FEB 2017 12:56AM EST | DOI: 10.1111/dom.12897

  11. ORIGINAL ARTICLES

    1. Scriptaid enhances skeletal muscle insulin action and cardiac function in obese mice

      Vidhi Gaur, Timothy Connor, Kylie Venardos, Darren C. Henstridge, Sheree D. Martin, Courtney Swinton, Shona Morrison, Kathryn Aston-Mourney, Stefan M. Gehrig, Roelof van Ewijk, Gordon S. Lynch, Mark A. Febbraio, Gregory R. Steinberg, Mark Hargreaves, Ken R. Walder and Sean L. McGee

      Accepted manuscript online: 2 FEB 2017 09:10PM EST | DOI: 10.1111/dom.12896

    2. Determinants of the Increase in Fasting Plasma Ketone Concentration during SGLT2 Inhibition in NGT, IFG and T2DM Patients

      Hussein Al Jobori, Giuseppe Daniele, John Adams, Eugenio Cersosimo, Curtis Triplitt, Ralph A. DeFronzo and Muhammad Abdul-Ghani

      Accepted manuscript online: 27 JAN 2017 06:35AM EST | DOI: 10.1111/dom.12881

  12. REVIEW ARTICLES

    1. The emerging role of Metformin in Gestational Diabetes Mellitus

      Susan G. Gray, Treasure McGuire, Neale Cohen and Peter J. Little

      Accepted manuscript online: 27 JAN 2017 02:16AM EST | DOI: 10.1111/dom.12893

  13. ORIGINAL ARTICLES

    1. You have full text access to this OnlineOpen article
      Safety and Efficacy of IDegLira Titrated Once Weekly versus Twice Weekly in Patients with Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Randomized Clinical Trial

      Stewart B. Harris, Győző Kocsis, Rudolf Prager, Terry Ridge, Keval Chandarana, Natalie Halladin and Serge Jabbour

      Accepted manuscript online: 26 JAN 2017 07:45AM EST | DOI: 10.1111/dom.12892

    2. You have full text access to this OnlineOpen article
      Novel oral glucose-lowering drugs compared to insulin are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia in type 2 diabetes patients

      Thomas Nyström, Johan Bodegard, David Nathanson, Marcus Thuresson, Anna Norhammar and Jan W. Eriksson

      Accepted manuscript online: 24 JAN 2017 05:00AM EST | DOI: 10.1111/dom.12889

    3. A pharmacological approach to understanding the control of insulin secretion in human islets

      Jean-Claude Henquin, Denis Dufrane, Valery Gmyr, Julie Kerr-Conte and Myriam Nenquin

      Accepted manuscript online: 24 JAN 2017 04:55AM EST | DOI: 10.1111/dom.12887

    4. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China

      Linong Ji, Puhong Zhang, Dongshan Zhu, Xian Li, Jiachao Ji, Juming Lu, Xiaohui Guo, Weiping Jia, Jianping Weng, Yangfeng Wu, Wenying Yang, Dajin Zou, Zhiguang Zhou, Changyu Pan, Yan Gao and Satish K. Garg

      Accepted manuscript online: 20 JAN 2017 12:55AM EST | DOI: 10.1111/dom.12886

    5. Liraglutide effects on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomised, placebo-controlled, double-blind, cross-over trial

      Bernt Johan von Scholten, Frederik Persson, Signe Rosenlund, Jesper Eugen-Olsen, Tomasz Pielak, Jens Faber, Tine Willum Hansen and Peter Rossing

      Accepted manuscript online: 20 JAN 2017 12:26AM EST | DOI: 10.1111/dom.12884

  14. BRIEF REPORTS

    1. Glucagon-Like Peptide-1 Agonists and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes

      Heidi Storgaard, Frederik Cold, Lise L. Gluud, Tina Vilsbøll and Filip K. Knop

      Accepted manuscript online: 20 JAN 2017 12:26AM EST | DOI: 10.1111/dom.12885

  15. ORIGINAL ARTICLES

  16. INVITED EDITORIALS

    1. Cardiovascular Effects of GLP-1 Receptor Agonist Therapies in Patients with Type-1 Diabetes

      Manfredi Rizzo, Ali A. Rizvi and Giorgio Sesti

      Accepted manuscript online: 18 JAN 2017 07:20AM EST | DOI: 10.1111/dom.12883

  17. ORIGINAL ARTICLES

    1. Immunohistochemical Assessment of Glucagon-like Peptide 1 Receptor (GLP-1R) Expression in the Pancreas of Patients with Type 2 Diabetes

      Rikke Kaae Kirk, Charles Pyke, Matthias G. von Herrath, Jane Preuss Hasselby, Lars Pedersen, Pia Gottrup Mortensen, Lotte Bjerre Knudsen and Ken Coppieters

      Accepted manuscript online: 17 JAN 2017 07:30AM EST | DOI: 10.1111/dom.12879

    2. Effect of valsartan on kidney outcomes in people with impaired glucose tolerance

      Gemma Currie, M. Angelyn Bethel, Björn Holzhauer, Steven M. Haffner, Rury R. Holman and John J. V. McMurray

      Accepted manuscript online: 17 JAN 2017 04:00AM EST | DOI: 10.1111/dom.12877

  18. BRIEF REPORTS

    1. You have full text access to this OnlineOpen article
      Renal Safety of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Patients With Type 2 Diabetes Mellitus

      Mehul Desai, Yshai Yavin, Dainius Balis, Don Sun, John Xie, William Canovatchel and Norm Rosenthal

      Accepted manuscript online: 12 JAN 2017 11:30PM EST | DOI: 10.1111/dom.12876

  19. ORIGINAL ARTICLES

    1. Dual Role of IL-1β in Islet Amyloid Formation and its β-Cell Toxicity: Implications in Type 2 Diabetes and Islet Transplantation

      Yoo Jin Park, Garth L. Warnock, Ziliang Ao, Nooshin Safikhan, Mark Meloche, Ali Asadi, Timothy J. Kieffer and Lucy Marzban

      Accepted manuscript online: 6 JAN 2017 02:20AM EST | DOI: 10.1111/dom.12873

    2. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndromes: the EXAMINE trial

      Simon R. Heller, Richard M. Bergenstal, William B. White, Stuart Kupfer, George L. Bakris, William C. Cushman, Cyrus R. Mehta, Steven E. Nissen, Craig A. Wilson, Faiez Zannad, Yuyin Liu, Noah M. Gourlie, Christopher P. Cannon and for the EXAMINE Investigators

      Accepted manuscript online: 6 JAN 2017 02:15AM EST | DOI: 10.1111/dom.12871

  20. BRIEF REPORTS

    1. Effect of gemigliptin on glycemic variability in patients with type 2 diabetes

      Se E. Park, Byung W. Lee, Jae H. Kim, Woo J. Lee, Jae H. Cho, Chang H. Jung, Seung H. Lee, Sunghwan. Suh, Gwong C. Hur, Sung H. Kim, Young H. Jang, Cheol Y. Park and STABLE Study Group

      Accepted manuscript online: 6 JAN 2017 01:20AM EST | DOI: 10.1111/dom.12869

  21. ORIGINAL ARTICLES

    1. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomised, placebo-controlled, double-blind, parallel-group study

      Christian Seerup Frandsen, Thomas Fremming Dejgaard, Henrik Ullits Andersen, Jens Juul Holst, Bolette Hartmann, Birger Thorsteinsson and Sten Madsbad

      Accepted manuscript online: 21 NOV 2016 01:18AM EST | DOI: 10.1111/dom.12830

VIEW

  1. 1 - 43

SEARCH

SEARCH BY CITATION